Evidence map›Paper›PMID 38891810›Full record

ArticleInternational journal of molecular sciences2024

Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass Density and Alendronate Treatment Failure in Patients with Primary Osteoporosis.

Werbson Lima Guaraná, Camilla Albertina Dantas Lima, Alexandre Domingues Barbosa, Sergio Crovella, Paula Sandrin-Garcia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Frontiers in endocrinology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Werbson Lima GuaranáKeizo Asami Institute, Biosciences Center, Federal University of Pernambuco, Recife Campus, Recife 50670-901, Brazil.ORCID 0000-0003-1806-5219
Camilla Albertina Dantas LimaKeizo Asami Institute, Biosciences Center, Federal University of Pernambuco, Recife Campus, Recife 50670-901, Brazil.ORCID 0000-0003-0320-3674
Alexandre Domingues BarbosaRheumatology Division, Clinical Hospital of Federal University of Pernambuco, Recife Campus, Recife 50740-900, Brazil.ORCID 0000-0002-8055-0509
Sergio CrovellaLaboratory of Animal Research Center (LARC), Qatar University, Doha P.O. Box 2713, Qatar.
Paula Sandrin-GarciaKeizo Asami Institute, Biosciences Center, Federal University of Pernambuco, Recife Campus, Recife 50670-901, Brazil.ORCID 0000-0003-4641-7429

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aminobisphosphonates (NBPs) are the first-choice medication for osteoporosis (OP); NBP treatment aims at increasing bone mineral density (BMD) by inhibiting the activity of farnesyl diphosphate synthase (FDPS) enzyme in osteoclasts. Despite its efficacy, inadequate response to the drug and side effects have been reported. The A allele of the rs2297480 (A > C) SNP, found in the regulatory region of the

Indexed as

AlendronateBone DensityBone Density Conservation AgentsGeranyltranstransferaseOsteoporosisPolymorphism, Single NucleotideTreatment FailureAgedAllelesCase-Control StudiesFemaleGenotypeHumansMaleMiddle AgedAlendronateBone Density Conservation AgentsGeranyltranstransferasealendronate sodiumaminobisphosphonatesFDPSgenetic variantpharmacogeneticpostmenopausal osteoporosis

Identifiers

PMID38891810
PMCPMC11172034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.